Drug middlemen once again were on the hot seat at a congressional hearing on Wednesday.
The hearing by the House Education and Workforce health subcommittee was about consolidation in the hospital and health insurance sectors. No hospital or insurance company representatives testified, but JC Scott, president of the pharmacy benefit manager lobbying group Pharmaceutical Care Management Association was tapped as a witness.
None of the other witnesses were sympathetic to the PBM industry. Even the sole PBM executive on the panel made clear at the outset that his nonprofit PBM is not a member of the PBM trade group.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect